Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20382274rdf:typepubmed:Citationlld:pubmed
pubmed-article:20382274lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:20382274lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:20382274lifeskim:mentionsumls-concept:C0003242lld:lifeskim
pubmed-article:20382274lifeskim:mentionsumls-concept:C0085732lld:lifeskim
pubmed-article:20382274lifeskim:mentionsumls-concept:C1817908lld:lifeskim
pubmed-article:20382274pubmed:issue6lld:pubmed
pubmed-article:20382274pubmed:dateCreated2010-5-11lld:pubmed
pubmed-article:20382274pubmed:abstractTextOur goal is to compare the immunogenicity and the extent of immunologic reactivity between bispecific and mono anti-idiotype vaccines. We previously obtained two human anti-Id antibody fragments fuse5-G22, fuse5-I50 by phage display technology which were mimics of the antigens from nasopharyngeal carcinoma cell line (HNE2). In this study, we developed and characterized a bispecific anti-Id antibody vaccine G22-I50 and its parent monovalent antibody vaccines G22 and I50. The efficacy of G22-I50, G22, and I50 as tumor vaccines was evaluated in Balb/c mice with three injections of these vaccines adjuvanted with Freund's adjuvant. Mice immunized with G22-I50 exhibited comparable levels of antibody titers and stronger binding inhibition capabilities. Spleen cells from G22-I50-immunized mice gave a significant proliferative response and higher expression level of IFN-gamma and IL-2.These results suggested that bispecific anti-Id antibody vaccine was able to induce more powerful humoral and cell-mediated immune responses, which might make it to be a potential vaccine candidate for the therapy of nasopharyngeal carcinoma.lld:pubmed
pubmed-article:20382274pubmed:languageenglld:pubmed
pubmed-article:20382274pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20382274pubmed:citationSubsetIMlld:pubmed
pubmed-article:20382274pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20382274pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20382274pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20382274pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20382274pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20382274pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20382274pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20382274pubmed:statusMEDLINElld:pubmed
pubmed-article:20382274pubmed:monthJunlld:pubmed
pubmed-article:20382274pubmed:issn1878-1705lld:pubmed
pubmed-article:20382274pubmed:authorpubmed-author:SongJieJlld:pubmed
pubmed-article:20382274pubmed:authorpubmed-author:LiuYan-HongYHlld:pubmed
pubmed-article:20382274pubmed:authorpubmed-author:LiGuan-ChengG...lld:pubmed
pubmed-article:20382274pubmed:authorpubmed-author:LiYue-HuiYHlld:pubmed
pubmed-article:20382274pubmed:authorpubmed-author:LiYa-LinYLlld:pubmed
pubmed-article:20382274pubmed:authorpubmed-author:GuoFeng-JieFJlld:pubmed
pubmed-article:20382274pubmed:authorpubmed-author:WangJia-JiaJJlld:pubmed
pubmed-article:20382274pubmed:copyrightInfoCopyright 2010 Elsevier B.V. All rights reserved.lld:pubmed
pubmed-article:20382274pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20382274pubmed:volume10lld:pubmed
pubmed-article:20382274pubmed:ownerNLMlld:pubmed
pubmed-article:20382274pubmed:authorsCompleteYlld:pubmed
pubmed-article:20382274pubmed:pagination707-12lld:pubmed
pubmed-article:20382274pubmed:meshHeadingpubmed-meshheading:20382274...lld:pubmed
pubmed-article:20382274pubmed:meshHeadingpubmed-meshheading:20382274...lld:pubmed
pubmed-article:20382274pubmed:meshHeadingpubmed-meshheading:20382274...lld:pubmed
pubmed-article:20382274pubmed:meshHeadingpubmed-meshheading:20382274...lld:pubmed
pubmed-article:20382274pubmed:meshHeadingpubmed-meshheading:20382274...lld:pubmed
pubmed-article:20382274pubmed:meshHeadingpubmed-meshheading:20382274...lld:pubmed
pubmed-article:20382274pubmed:meshHeadingpubmed-meshheading:20382274...lld:pubmed
pubmed-article:20382274pubmed:meshHeadingpubmed-meshheading:20382274...lld:pubmed
pubmed-article:20382274pubmed:meshHeadingpubmed-meshheading:20382274...lld:pubmed
pubmed-article:20382274pubmed:meshHeadingpubmed-meshheading:20382274...lld:pubmed
pubmed-article:20382274pubmed:meshHeadingpubmed-meshheading:20382274...lld:pubmed
pubmed-article:20382274pubmed:meshHeadingpubmed-meshheading:20382274...lld:pubmed
pubmed-article:20382274pubmed:meshHeadingpubmed-meshheading:20382274...lld:pubmed
pubmed-article:20382274pubmed:meshHeadingpubmed-meshheading:20382274...lld:pubmed
pubmed-article:20382274pubmed:meshHeadingpubmed-meshheading:20382274...lld:pubmed
pubmed-article:20382274pubmed:meshHeadingpubmed-meshheading:20382274...lld:pubmed
pubmed-article:20382274pubmed:meshHeadingpubmed-meshheading:20382274...lld:pubmed
pubmed-article:20382274pubmed:meshHeadingpubmed-meshheading:20382274...lld:pubmed
pubmed-article:20382274pubmed:year2010lld:pubmed
pubmed-article:20382274pubmed:articleTitleThe ability of human bispecific anti-idiotype antibody to elicit humoral and cellular immune responses in mice.lld:pubmed
pubmed-article:20382274pubmed:affiliationTumor Immunobiology Laboratory of Cancer Research Institution, Central South University, Changsha 410078, Hunan, China.lld:pubmed
pubmed-article:20382274pubmed:publicationTypeJournal Articlelld:pubmed